1. Efficacy and tolerability of transdermal granisetron for the control of chemotherapy-induced nausea and vomiting associated with moderately and highly emetogenic multi-day chemotherapy: a randomized, double-blind, phase III study.
- Author
-
Boccia RV, Gordan LN, Clark G, Howell JD, and Grunberg SM
- Subjects
- Administration, Cutaneous, Administration, Oral, Adult, Aged, Antiemetics administration & dosage, Antiemetics adverse effects, Antineoplastic Agents adverse effects, Antineoplastic Agents therapeutic use, Delayed-Action Preparations, Double-Blind Method, Female, Granisetron administration & dosage, Granisetron adverse effects, Humans, Male, Middle Aged, Nausea chemically induced, Neoplasms drug therapy, Vomiting chemically induced, Antiemetics therapeutic use, Granisetron therapeutic use, Nausea prevention & control, Vomiting prevention & control
- Abstract
Purpose: A novel transdermal formulation of granisetron (the granisetron transdermal delivery system (GTDS)) has been developed to deliver granisetron continuously over 7 days. This double-blind, phase III, non-inferiority study compared the efficacy and tolerability of the GTDS to daily oral granisetron for the control of chemotherapy-induced nausea and vomiting (CINV)., Patients and Methods: Six hundred forty-one patients were randomized to oral (2 mg/day, 3-5 days) or transdermal granisetron (one GTDS patch, 7 days), before receiving multi-day chemotherapy. The primary endpoint was complete control of CINV (no vomiting/retching, no more than mild nausea, no rescue medication) from chemotherapy initiation until 24 h after final administration. The prespecified non-inferiority margin was 15%., Results: Five hundred eighty-two patients were included in the per protocol analysis. The GTDS displayed non-inferiority to oral granisetron: complete control was achieved by 60% of patients in the GTDS group, and 65% in the oral granisetron group (treatment difference, -5%; 95% confidence interval, -13-3). Both treatments were well tolerated, the most common adverse event being constipation., Conclusions: The GTDS provides effective, well-tolerated control of CINV associated with moderately or highly emetogenic multi-day chemotherapy. It offers a convenient alternative route for delivering granisetron for up to 7 days that is as effective as oral granisetron.
- Published
- 2011
- Full Text
- View/download PDF